4,787 Shares in IQVIA Holdings Inc. (NYSE:IQV) Purchased by Hickory Asset Management Inc.

Hickory Asset Management Inc. purchased a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 4,787 shares of the medical research company’s stock, valued at approximately $941,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. FMR LLC increased its holdings in IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after acquiring an additional 804,963 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after purchasing an additional 583,396 shares in the last quarter. Impax Asset Management Group plc grew its holdings in shares of IQVIA by 9.7% in the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock valued at $423,885,000 after purchasing an additional 157,809 shares in the last quarter. Nordea Investment Management AB boosted its stake in IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after buying an additional 452,029 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in IQVIA by 3.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,226,083 shares of the medical research company’s stock worth $290,545,000 after buying an additional 39,772 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Down 1.2 %

NYSE IQV opened at $193.65 on Friday. The business has a fifty day moving average price of $200.59 and a 200 day moving average price of $218.51. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.81 and a current ratio of 0.84. The company has a market cap of $35.15 billion, a P/E ratio of 25.82, a P/E/G ratio of 2.25 and a beta of 1.48.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Research analysts anticipate that IQVIA Holdings Inc. will post 10.81 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on IQV. Stifel Nicolaus dropped their price objective on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Royal Bank of Canada reissued an “outperform” rating and set a $270.00 target price on shares of IQVIA in a research note on Monday, February 10th. The Goldman Sachs Group lowered their target price on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Bank of America lowered their target price on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Finally, UBS Group lowered their target price on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Five research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $251.67.

Insider Activity at IQVIA

In other news, Director John G. Danhakl bought 1,275 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The stock was bought at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the acquisition, the director now directly owns 1,275 shares of the company’s stock, valued at $255,739.50. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. 1.60% of the stock is currently owned by company insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.